Themis Bioscience

Closed

Themis Bioscience is a biotech company.

Business Model: B2B

About

Themis Bioscience developed vaccines and immune-modulation therapies for infectious diseases. The company applied a platform based on original Institut Pasteur discoveries and was developing vaccine programs for diseases including SARS, Chikungunya, MERS, Lassa fever, and COVID-19. Merck announced in 2020 that a subsidiary would acquire all outstanding Themis shares, making the company a wholly owned Merck subsidiary when the transaction closed.

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare

Growth EquityTotal funding$5.1BAug 2022

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare

Private EquityTotal funding$3.9BJan 2019

Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare

Private EquityTotal funding$3.0BJan 2004

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech

Series ATotal funding$3.0BJan 2022

Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare

Private EquityTotal funding$3.0BMay 2017

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology

Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

<a href="https://indexed.vc/companies/themis-bioscience"><img src="https://indexed.vc/api/badge/company/themis-bioscience" alt="Themis Bioscience on Indexed.vc" width="260" height="76" /></a>